Population Pharmacokinetic-Pharmacodynamic Modeling of TF-505 Using Extension of Indirect Response Model by Incorporating a Circadian Rhythm in Healthy Volunteers(Biopharmacy)

概要

論文の詳細を見る
The pharmacokinetic-pharmacodynamic (PK-PD) relationship of the newly developed drug, (-)-(S)-4-[1-[4-[1-(4-isobutylphenyl)butoxy]benzoyl]indolizin-3-yl]butyric acid (TF-505), was characterized via a population approach in early human study. Healthy volunteers were divided into six groups. The groups received four single doses (25, 50, 75 or 100mg) and 2 multiple doses (12.5 or 25mg) of TF-505, respectively. Dihydrotestosterone (DHT) data were collected to assess TF-505 pharmacodynamics. Population PK/PD modeling of TF-505 was performed via mixed-effects modeling using the NONMEM software package. The final PK-PD model incorporates a two-compartment PK model and an extended indirect PD model. The population PK parameters were 0.197h^<-1> for the κ_a, 0.0678h^<-1> for κ_e, 12.51 for V_c, 0.0645h^<-1> for κ_<12>, 0.0723h^<-1> for κ_<21>. Extension of indirect response model by incorporating a time-dependent periodic function for κ_<in> takes into account the chronopharmacologic rhythms (I_<max>: 0.706±0.297, IC_<50>: 1.01±1.64 (μg/ml), κ_<out>: 0.221±0.0486 (h^<-1>), R_m: 20.4±8.08 (%h^<-1>), R_<amp>: 5.06±3.43 (%h^<-1>), T_z: 5.01±0.407(h) (Population mean±S.E.)). R_m is the mean DHT synthesis rate, R_<amp> is the amplitude of the DHT synthesis rate, and T_z is the acrophase time, signifying maximum synthesis rate. The present study represents a successful population PK-PD model using the full data from early human studies. The population parameters thus obtained could provide useful indicators for the determination of dosage regimens in exploratory studies in patient populations.
公益社団法人日本薬学会の論文
2005-08-01

Population Pharmacokinetic-Pharmacodynamic Modeling of TF-505 Using Extension of Indirect Response Model by Incorporating a Circadian Rhythm in Healthy Volunteers(Biopharmacy)

スポンサーリンク

概要

著者

関連論文

スポンサーリンク